Are you a breast cancer patient?
Information about the Digistain test for patients…
delivered faster than ever before
About Your Digistain Result
We understand that a cancer diagnosis can be overwhelming, with a flood of information to process. Digistain reports are usually returned within 1-2 days of specimen receipt at our UK laboratory (courier transit is additional). We are here to help you support informed discussions with your medical team into your testing and treatment options.
Our mission is to empower you to take the next steps promptly, with confidence and clarity.
Why Digistain?
Digistain is a risk-profiling test registered with the Medicines and Healthcare products Regulatory Agency (MHRA) and UKCA-marked under the UK Medical Devices Regulations 2002 for breast cancer patients. It provides your clinical team with additional information about the risk of recurrence; treatment decisions remain with your oncologist.
Your treating team will confirm whether Digistain is appropriate for you. It is intended for patients diagnosed with ER-positive, HER2-negative, Stage 1 or 2 invasive breast cancer with no more than 3 involved lymph nodes.
The test has been designed by cancer researchers at Imperial College London with two things in mind to better serve the needs of patients – TIME and COST.
TIME: The test is very fast which Treatment decisions remain with your oncologist.
COST: We are committed to reducing economic barriers in healthcare. The technology behind Digistain enables the test to be generated at a lower cost than genomic testing alternatives.
Designed for invasive breast cancer patients who are:
Digistain is intended for patients with ER-positive, HER2-negative, Stage 1 or 2 invasive breast cancer and no more than 3 involved lymph nodes.
Breast cancer survivor Samantha Womack in conversation with Digistain
Digistain is reimbursed by selected health insurance providers. Enquire with your local insurance provider to check if you are covered.
Subscribe to leading news and insights
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.
Digistain Prognostic Score – Breast is an in vitro diagnostic test for professional use. The result is an estimate of the risk of recurrence and is probabilistic. It is used with, and does not replace, established clinico-pathological factors and clinical judgement. Treatment decisions remain with the treating clinician.